UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): DECEMBER 5, 2017

MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)

DELAWARE
001-37758
47-4671997
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)

2575 WEST BELLFORT, SUITE 333, HOUSTON TX 77054
(Address of principal executive offices and zip code)

(713) 300-5160
(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]



Item 8.01 Other Events.
On December 5, 2017 at 11:30 a.m. (Pacific Time), Moleculin Biotech, Inc. (the “Company”) will be a presenting company at the 10th Annual LD Micro Main Event Conference. Representatives of the Company will use the presentation set forth as Exhibit 99.1 herein in connection with the foregoing presentation and in various meetings with investors from time to time.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit No.    Description


    

SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLECULIN BIOTECH, INC.
Date: December 5, 2017
By:     /s/ Jonathan Foster ________
Jonathan Foster
Chief Financial Officer


2



EXHIBIT INDEX
Exhibit No.      Description



3

Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Moleculin Biotech Charts.
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Moleculin Biotech Charts.